Abstract

BackgroundThe Expanded Program on Immunization (EPI) is the most cost-effective measures to control vaccine-preventable diseases. Currently, the EPI schedule is similar for HIV-infected children; the introduction of antiretroviral therapy (ART) should considerably prolong their life expectancy.Methods and Principal FindingsTo evaluate the persistence of antibodies to the EPI vaccines in HIV-infected and HIV-exposed uninfected children who previously received these vaccines in routine clinical practice, we conducted a cross-sectional study of children, aged 18 to 36 months, born to HIV-infected mothers and living in Central Africa. We tested blood samples for antibodies to the combined diphtheria, tetanus, and whole-cell pertussis (DTwP), the measles and the oral polio (OPV) vaccines. We enrolled 51 HIV-infected children of whom 33 were receiving ART, and 78 HIV-uninfected children born to HIV-infected women. A lower proportion of HIV-infected children than uninfected children had antibodies to the tested antigens with the exception of the OPV types 1 and 2. This difference was substantial for the measles vaccine (20% of the HIV-infected children and 56% of the HIV-exposed uninfected children, p<0.0001). We observed a high risk of low antibody levels for all EPI vaccines, except OPV types 1 and 2, in HIV-infected children with severe immunodeficiency (CD4+ T cells <25%).Conclusions and SignificanceChildren were examined at a time when their antibody concentrations to EPI vaccines would have still not undergone significant decay. However, we showed that the antibody concentrations were lowered in HIV-infected children. Moreover, antibody concentration after a single dose of the measles vaccine was substantially lower than expected, particularly low in HIV-infected children with low CD4+ T cell counts. This study supports the need for a second dose of the measles vaccine and for a booster dose of the DTwP and OPV vaccines to maintain the antibody concentrations in HIV-infected and HIV-exposed uninfected children.

Highlights

  • Pediatric HIV infection is a major public health threat

  • We evaluated the persistence of antibody levels in HIV-infected and HIV-exposed uninfected children born to HIVinfected mothers, living in Central Africa and who previously received Expanded Program on Immunization (EPI) vaccines in routine clinical practice

  • Composite categorical variables were created to evaluate the effect of HIV infection: i) HIV status combined with the percentage of CD4+ T cells (HIV-exposed uninfected, HIV infected and $25% CD4+ T cells, HIV infected and,25% CD4+ T cells) [10]; ii) HIV status combined with HIV viral load (VL) (HIVexposed uninfected, HIV infected and VL,10,000 copies/ml, HIV infected and VL $10,000 copies/ml) [11]; and iii) HIV status combined with duration of antiretroviral therapy (ART) (HIV-exposed uninfected, HIV infected and $6 months ART, HIV infected and,6 months of ART or no ART)

Read more

Summary

Introduction

Pediatric HIV infection is a major public health threat. Two thirds of the 700,000 [630,000 to 820,000] children less than 15 years old newly infected with HIV in 2005 were living in sub-Saharan Africa [1]. Mother to child transmission of HIV is still a major route of infection for children This is related mainly to insufficient access to prevention methods, HIV screening and antiretroviral treatment (ART) in developing countries. A lower proportion of HIV-infected children than uninfected children had antibodies to the tested antigens with the exception of the OPV types 1 and 2. This difference was substantial for the measles vaccine (20% of the HIV-infected children and 56% of the HIV-exposed uninfected children, p,0.0001). This study supports the need for a second dose of the measles vaccine and for a booster dose of the DTwP and OPV vaccines to maintain the antibody concentrations in HIV-infected and HIV-exposed uninfected children

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call